Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) is a clinical-stage biopharmaceutical company developing small-molecule medicines for serious skeletal and cardiac muscle diseases. Its proprietary drug discovery platform uses muscle biology, functional assays and medicinal chemistry to identify compounds targeting proteins… From the company’s description.
In fiscal 2025, Edgewise Therapeutics, Inc. reported a net loss of $167.79M. Operations used $143.82M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Edgewise Therapeutics, Inc. does
In the company’s own words
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) is a clinical-stage biopharmaceutical company developing small-molecule medicines for serious skeletal and cardiac muscle diseases. Its proprietary drug discovery platform uses muscle biology, functional assays and medicinal chemistry to identify compounds targeting proteins involved in muscle function. The company’s lead candidate, sevasemten, is an oral fast skeletal-muscle myosin inhibitor being studied for Duchenne and Becker muscular dystrophies. Its cardiac programs include EDG-7500, a cardiac sarcomere modulator in Phase 2 trials for obstructive and nonobstructive hypertrophic cardiomyopathy, and EDG-15400, in a Phase 1 trial with a future target of heart failure with preserved ejection fraction. The preclinical EDG-003 program explores candidates for cardiometabolic diseases. Edgewise retains global development and commercialization rights to its programs. It has clinical-stage programs in muscular dystrophies and cardiac diseases, alongside preclinical research, and is developing therapies for conditions with limited or no approved treatment options.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOULDER, CO
- Fiscal year end
- December
- CIK
- 1710072
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Edgewise Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Edgewise Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Edgewise Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Edgewise Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Edgewise Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”